Form 4: Eli Lilly Executive Patrik Jonsson Reports Stock Transactions

Eli Lilly executive Patrik Jonsson reported the acquisition and disposal of company stock and restricted stock units on February 1, 2024.

Summary

• Patrik Jonsson, an Executive Vice President at Eli Lilly, filed a Form 4 detailing changes in his beneficial ownership of company stock.
• On February 1, 2024, Jonsson acquired 4,124 shares of common stock through the vesting of restricted stock units.
• Also on February 1, 2024, Jonsson disposed of 1,844 shares of common stock at a price of $645.61 per share.
• Following these transactions, Jonsson directly owns 39,221 shares of Eli Lilly common stock and indirectly owns 537 shares through a 401(k) plan.
• The restricted stock units that vested also represent a contingent right to receive one share of Eli Lilly common stock each.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of stock transactions, which is neither positive nor negative in itself. It reflects standard executive compensation practices.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, which is common practice for publicly traded companies.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, and Eli Lilly's filing is consistent with these requirements.
• Executives at comparable pharmaceutical companies such as Pfizer, Johnson & Johnson, and Merck also regularly file Form 4s to report their stock transactions.

Stakeholder Impact

• The transactions have a minimal impact on shareholders as they are part of standard executive compensation practices.

Key Dates

Keywords

Form 4, Beneficial Ownership, Stock Transactions, Restricted Stock Units, Eli Lilly, Executive Compensation, Insider Trading